Assistant Professor, Harvard Medical School
Oncology
Dr. Jacob P. Laubach, MD
|
|
Give Review
Jacob Laubach practices Oncology. He studied medicine at Duke University School of Medicine. Duke University School of Medicine is a top medical university. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. Jacob P. Laubach, MD has written publications. He has 60 publications published with PubMed. The lastest publication is: 'Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Panobinostat for the Treatment of Multiple Myeloma.
- Panobinostat for the treatment of relapsed or relapsed/refractory multiple Myeloma: pharmacology and clinical outcomes.
- Development of a conceptual model to illustrate the impact of multiple Myeloma and its treatment on health-related quality of life.
- Extramedullary Waldenström Macroglobulinemia.
- Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant.
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple my...
- Novel Targeted Agents in the Treatment of Multiple Myeloma.
- Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple Myeloma.
- Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy.
- Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple Myeloma.
- Outcomes in patients with relapsed or refractory multiple Myeloma in a phase I study of everolimus in combination with lenalidomide.
- Having a heavy heart: approaches to infiltrative cardiomyopathy.
- Current strategies for treatment of relapsed/refractory multiple Myeloma.
- Daratumumab granted breakthrough drug status.
- Elotuzumab : a novel anti-CS1 monoclonal antibody for the treatment of multiple Myeloma.
- Phase transitions in human IgG solutions.
- IgD and IgE variants of Myeloma: valuable insights and therapeutic opportunities.
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients.
- Kidney Disease and Multiple Myeloma.
- Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple Myeloma.
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple Myeloma who have received lenalidomide and bortezomib.
- Tumor promoting immune suppressive Myeloid derived suppressor cells in multiple myeloma microenvironment.
- Peripheral neuropathy in multiple Myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.
- Methyljasmonate displays in vitro and in vivo activity against multiple myeloma Cells.
- Pathological crystallization of human immunoglobulins.
- The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms(*).
- Management of relapsed and relapsed/refractory multiple Myeloma.
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple Myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
- Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in Myeloma.
- A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple Myeloma.
- The spectrum of kidney involvement in Lymphoma: a case report and review of the literature.
- Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through Systematic combination screening in B-cell malignancies.
- The evolution and impact of therapy in multiple Myeloma.
- Complications of multiple Myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
- Novel therapies in the treatment of multiple Myeloma.
- Emerging treatments for multiple Myeloma: beyond immunomodulatory drugs and bortezomib.
- Finding the right academic job.
- Management of Myeloma-associated renal dysfunction in the era of novel therapies.
- Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple Myeloma.
- Bortezomib in the management of multiple Myeloma.
- Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other Cancers.
- Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
- Hematology: Thalidomide maintenance in multiple Myeloma.
- Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
- The use of novel agents in the treatment of relapsed and refractory multiple Myeloma.
- Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3.
- Maximizing the clinical benefit of novel therapies in multiple Myeloma.
- Molecular and Cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
- Hematology: Bortezomib and dexamethasone induction for multiple Myeloma.
- Latest advances and current challenges in the treatment of multiple Myeloma.
- Lenalidomide targets clonogenic side population in multiple Myeloma: pathophysiologic and clinical implications.
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple Myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
- Hematology: Setting the standard for newly diagnosed multiple Myeloma.
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I...
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports ...
- The treatment of multiple Myeloma patients not eligible for asct.
- Tailoring treatment for multiple myeloma patients with relapsed and refractory Disease.
- Lenalidomide in multiple Myeloma: an evidence-based review of its role in therapy.
- Current and emerging strategies for the management of Acute myeloid leukemia in the elderly.
Schools
Duke University School Of Medicine
Duke University Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Duke University Hospital -
Duke University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1922086487 | |
| NPPES Provider LastName | LAUBACH | |
| NPPES Provider FirstName | JACOB | |
| NPPES Provider ZIPCode | 021156013 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 393.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 5.6 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1922086487 |
| Last Name Of The Provider | LAUBACH |
| First Name Of The Provider | JACOB |
| View All |
Similar Doctors
|
|
Dr. Richard T. Penson, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Elizabeth A. Guancial, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason E. Faris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judson M. Englert, MD |
|
|
Dr. Wendy Y. Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara E. Bierer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruth M. Ruprecht, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael Hassett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Rabin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip J. Saylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anuj Mahindra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andreea M. Negroiu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen H. Antman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew M. Evens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sandra L. Dabora, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer L. Westrup, MD
This Doctor is OpenDoctor Recommended.
|